The Constipation Treatment Market was valued for $5.88 billion in 2022 and is estimated to reach $10.12 billion by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032. Constipation occurs when your bowel movements become less frequent, and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber. Symptoms include hard stools, stomach cramps, bloating, and nausea. People with long-term constipation can develop hemorrhoids (piles), fecal impaction where dry, hard stools collect in the rectum, and bowel incontinence (the leakage of liquid stools).
The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.
Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market.
In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.
The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.
The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.
Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market.
In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.
The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the constipation treatment market analysis from 2022 to 2032 to identify the prevailing constipation treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the constipation treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global constipation treatment market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Product Type
- Others
- Mu-Opioid Receptor Antagonists
- Laxative
- Chloride Channel-2 Activator
- Guanylate Cyclase-C (GC-C) Agonist
By Disease Type
- Opioid-Induced Constipation
- Chronic Idiopathic Constipation
- Irritable Bowel Syndrome with Constipation
By Prescription Type
- Prescribed Drugs
- Over-the-Counter Drugs
By Distribution Channel
- Online Pharmacy
- Drug Store and Retail Pharmacy
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Europe
- LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Abbott Laboratories
- Bausch Health Companies Inc.
- Bayer AG
- Ironwood Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Ltd.
- Prestige Consumer Healthcare Inc.
- Ardelyx Inc.
- Sanofi S.A.
- AstraZeneca plc
- AbbVie Inc.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE
CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE
CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE
CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to this report, the constipation treatment market was valued at $5.9 billion in 2022, and is estimated to reach $10.1 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.Chronic constipation is infrequent bowel movements or difficulty in passage of stools that persists for several weeks or longer. Constipation is generally described as having fewer than three bowel movements a week. Signs and symptoms of chronic constipation include having lumpy or hard stools, straining to have bowel movements, and feeling as though there is a blockage in the rectum that prevents bowel movements.
There are different types of drugs used for constipation treatment such as opioid antagonist, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others such as selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. The disease types of constipation include opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation (IBS-C). Prescription type for constipation treatment includes prescribed drugs and over-the-counter drugs. Distribution channel for constipation drugs are online pharmacy, drug store & retail pharmacy and others which includes hospital pharmacies and general stores.
Key factors driving the growth of the constipation treatment market include rise in prevalence of chronic diseases such as cancer, high presence of market players, and surge in number of geriatric populations. Moreover, increase in number of adoptions of key strategies such as business expansion, partnership, agreement and others are anticipated to boost the growth of market. For instance, in February 2022, Ardelyx, Inc., a biopharmaceutical company, announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners (SLR). This agreement includes the launch and commercialization of IBSRELA for the treatment of irritable bowel syndrome with constipation in adults. This financing further strengthens the balance sheet and extends the cash runway offering operational flexibility to further support the launch of IBSRELA.
In addition, Rise in prevalence of opioid induced constipation and increase in number of product provision for opioid antagonist are anticipated to boost the growth of market. For instance, the opioid antagonist commonly used in treatment of opioid induced constipation are Relistor by Salix Pharma (Bausch Health), Moventig (naloxegol) by AstraZeneca plc., and Movantik by Cosmo Pharmaceuticals. Moreover, high presence of market players who manufacture opioid antagonists and rise in the number of product launches for opioid antagonists are anticipated to boost growth of the constipation treatment market.
Moreover, increase in prevalence of chronic idiopathic constipation and rise in availability of laxatives for treatment of constipation are anticipated to drive the growth of market. For instance, Duphalac by Abbott, a pharmaceutical company, Dilcoflex by Sanofi, and MiraLAX by Bayer AG are some laxatives used in the treatment of chronic idiopathic constipation. Moreover, rise in prevalence of constipation is expected to drive the growth of market. For instance, according to report published by National Library of Medicine, in July 2023, a systematic literature review revealed that constipation has a global prevalence of approximately 14.0%. Thus, increase in prevalence of constipation, rise in number of product launches, and high presence of market players are anticipated to boost the growth of market.
The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Region wise, it is analyzed across North America (the U. S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players profiled in the study Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market.
Key Market Insights
By product type, laxative segment was the highest revenue contributor to the market and is estimated to reach $3.75 billion by 2032, with a CAGR of 4.9%.By disease type, the chronic idiopathic constipation segment dominated the global market. However, the opioid-induced constipation segment is expected to be the fastest-growing segment with a CAGR of 6.2% during the forecast period.
By prescription type, the prescribed drugs segment dominated the global market. However, the over-the-counter drugs segment is expected to be the fastest-growing segment with a CAGR of 5.9% during the forecast period.
By distribution channel, the drug store and retail pharmacy segment dominated the global market. However, the online pharmacy segment is expected to be the fastest-growing segment with a CAGR of 6.3% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 6.4% during the forecast period
Companies Mentioned
- Abbott Laboratories
- Bausch Health Companies Inc.
- Bayer AG
- Ironwood Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Ltd.
- Prestige Consumer Healthcare Inc.
- Ardelyx Inc.
- Sanofi S.A.
- AstraZeneca plc
- AbbVie Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
